Skip to main content
Download PDF
Download ePub

Effects of low-dose magnesium oxide on elevated serum magnesium levels and improved constipation in hemodialysis patients: a single-center retrospective study

Renal Replacement Therapy volume 10, Article number: 30 (2024) Cite this article

Abstract

Background

The prevention of hypomagnesemia is critical for improving the life expectancy of patients undergoing hemodialysis (HD). The administration of magnesium oxide (MgO) increases serum Mg concentrations; however, dose adjustments must be done carefully owing to the risk of hypermagnesemia in patients undergoing HD. Additionally, the laxative effects of low-dose MgO on constipation in these patients has not been reported. Therefore, in the present study, we investigated the effects of treatment with low-dose MgO on serum Mg concentration changes and the improvement of defecation in patients undergoing HD.

Methods

The present study was a single-center retrospective observational study of 43 patients undergoing maintenance HD at Shirasagi Hospital. The patients’ clinical characteristics, including serum Mg concentration, were obtained from the hospital’s electronic medical records. In the group who received MgO for constipation, the effectiveness of MgO as a laxative was categorized as effective, ineffective, or unknown on the basis of electronic medical records related to defecation.

Results

Of the 43 patients included in the present study, 23 were prescribed supplemental Mg to prevent hypomagnesemia or maintain mild hypermagnesemia and 19 to prevent constipation. All patients received diasylate with an Mg concentration of 1.0 mEq/L. Additionally, 37 patients (86%) were treated with 330 mg/day MgO. The serum Mg concentrations before and 1, 2, and 3 months after the start of MgO were 2.3 ± 0.2, 2.8 ± 0.4, 2.8 ± 0.5, and 2.8 ± 0.4 mg/dL, respectively (P < 0.001). Multiple linear regression analysis showed that dry weight was independently associated with changes in serum Mg concentration from before to 1 month after MgO administration (regression coefficient = −0.027; P = 0.020). Of the 19 patients evaluated for constipation, 8 (42%) had documented effective bowel movements after the initiation of MgO, 6 had no effect, and 5 were unknown; however, 1 patient in the ineffective group and 2 in the effective group used other laxatives prior to starting MgO.

Conclusions

The results of the present study suggest that the administration of low-dose MgO to patients undergoing HD provides a means of increasing serum Mg concentration without causing dangerous hypermagnesemia, that serum Mg concentrations increase relatively easily in lower-weight patients. In addition, this study shows that low-dose MgO may be effective as an initial treatment for constipation in this patient group in a cautious manner, but this study did not provide sufficient data for the usefulness of low-dose MgO for constipation in patients undergoing HD.

Background

Patients undergoing maintenance hemodialysis (HD) are at a higher risk of dying from cardiovascular disease [1]. Recently, several studies identified hypomagnesemia as a factor associated with mortality in these patients [2, 3]. Additionally, mild hypermagnesemia is associated with a lower risk of hip fracture [4] while buffering the increased risk of cardiovascular mortality owing to hyperphosphatemia [5] in patients undergoing HD. Therefore, the prevention of hypomagnesemia in patients undergoing HD is critical to improving poor prognosis.

The oral administration of magnesium (Mg) is a simple and effective approach to increase serum Mg concentrations. In fact, Bressendorff et al. [6] reported that oral Mg supplementation improved T50, the time point at which calcium-protein particles are converted from primary to secondary, in patients with stage 3 and 4 chronic kidney disease (CKD). Some studies, however, have reported that oral Mg supplementation in nondialyzed patients with CKD reduced the risk of coronary artery calcification [7], while others have reported that it did not change the risk [8]; therefore, a consensus has yet been reached. On the other hand, multiple studies have shown that a low T50 is associated with poor prognosis in patients undergoing HD [9, 10]. As a whole, patients undergoing HD are at an extremely high risk for developing hypermagnesemia after the administration of Mg as a result of their significantly impaired renal function. Therefore, to avoid hypomagnesemia, it is important to determine the safe dosages of magnesium oxide (MgO) in patients undergoing HD.

Patients undergoing dialysis often experience chronic constipation, which has recently been shown to be associated with low mortality [11, 12] and peritoneal dialysis-related peritonitis [13]. The improvement of chronic constipation in these patients is, therefore, important from the perspective of improving poor prognoses. MgO is a safe and effective salt laxative used in patients with normal renal function; however, its effect is dose-dependent because MgO is converted to the osmotic substances magnesium chloride (MgCl2) and magnesium bicarbonate (Mg(HCO3)2), which increase defecation. In contrast, Mg is primarily excreted by the kidneys and, therefore, cannot be administered at normal doses to patients with impaired renal function, including those undergoing dialysis, owing to the increased risk of hypermagnesemia [14, 15]. There are no reports, however, on the effectiveness of low-dose MgO supplementation, which can be safely used in patients undergoing dialysis, in treating constipation.

The present retrospective study, therefore, aimed to determine the effects of low-dose MgO on both serum Mg concentrations and constipation in patients undergoing HD.

Methods

Patients and study design

The present study was a single-center, retrospective, observational study, which included patients undergoing maintenance HD at Shirasagi Hospital (Osaka, Japan) who were prescribed MgO for at least 3 months between January 2017 and May 2023. Patients with no serum Mg concentration data prior to the start of MgO therapy, as well as those who started MgO < 2 months after the initiation of HD, were excluded.

Data collection

Demographic and clinical characteristics, including age, sex, cause of end-stage kidney disease, duration of dialysis, dry weight (DW), dialysis method, standardized dialysis volume (Kt/V), normalized protein catabolic ratio (nPCR), purpose of MgO prescription, laboratory data, and concomitant drugs were obtained from the electronic medical records maintained by Shirasagi Hospital. Serum Mg concentrations were measured prior to the start of MgO administration and every month for 3 months thereafter. In the group prescribed MgO for constipation, the effectiveness of MgO as a laxative was categorized as effective, ineffective, or unknown on the basis of electronic medical records related to defecation.

Ethical considerations

The protocol for the present study was approved by the Shirasagi Hospital Ethics Committee at Shirasagi Hospital (approval number JCR2023004) and was performed in accordance with the Declaration of Helsinki.

Statistical analyses

Normality of the distribution was examined using the Shapiro–Wilk test, and data with normal distributions are presented as mean ± standard deviation, while those with nonnormal distributions are presented as medians with ranges. One-way analysis of variance (ANOVA) was used to compare serum Mg concentrations before and after the administration of MgO. The associations between these changes in serum Mg concentrations and patient background factors were evaluated using the Spearman rank correlation test and stepwise multiple linear regression analysis. Data with nonnormal distributions were log-transformed using multiple linear regression analysis. All statistical analyses were performed using EZR, which is a modified version of the R commander equipped with statistical functions for medical statistics [16]

Results

Baseline patient demographics and clinical characteristics

The baseline demographic and clinical characteristics of the 43 patients undergoing HD included in the present study are shown in Table 1.

Table 1 Patient characteristics
Full size table

Of the 43 patients included in the present study, 22 were treated with HD, 20 with online hemodiafiltration (HDF), and 1 with intermittent HDF infusion. The dialysate Mg concentration was 1.0 mEq/L in all patients, and the baseline serum Mg concentration was 2.3 ± 0.2 mg/dL.

Dosage and purpose of MgO

The purpose of the prescriptions and MgO dosages are listed in Table 2.

Table 2 Dosage and purpose of MgO
Full size table

Of the 43 patients included in the present study, 23 were prescribed Mg supplementation to prevent hypomagnesemia or maintain mild hypermagnesemia and 19 were prescribed Mg supplementation for constipation. The doses were as follows: 37 patients (86%) received 330 mg/day; 3 with 660 mg/day; and 1 with 990 mg/day.

Change in serum Mg level after MgO administration

Figure 1 shows the trend in serum Mg concentrations from before to 3 months after the initiation of MgO treatment, reflecting that serum Mg concentrations increased significantly after the initiation of MgO administration. No cases of symptomatic hypermagnesemia were suspected during the study period, and the two patients (5%) that experienced serum Mg concentrations of 4.0 mg/dL or higher continued on at a reduced MgO dosage.

Fig. 1
figure 1

Change in serum Mg level before and after administration of MgO; open circle: preMgO; closed circle: postMgO

Full size image

Correlation between change in serum Mg and patient characteristics

Table 3 shows the results of the investigation of the factors associated with changes in serum Mg concentration after 1 month of MgO administration in 32 patients receiving an MgO dose of 330 mg/day.

Table 3 Correlation between the serum Mg change and patients’ characteristics
Full size table

DW was negatively correlated with changes in serum Mg concentration (ρ =  − 0.360; P = 0.043; Fig. 2). Multiple linear regression analysis showed that DW was associated with variations in serum Mg concentration, independent of serum albumin concentration, baseline serum Mg concentration, and the Kt/V ratio (regression coefficient =  −0.027; P = 0.020).

Fig. 2
figure 2

Correlation between the serum Mg change and patient characteristics. A dry weight; B serum albumin; C standardized dialysis volume

Full size image

Subgroup analysis of patients prescribed MgO for constipation

The laxative effects of the 19 MgO prescriptions for constipation are shown in Fig. 3. The electronic medical records indicated that 8 of the 19 patients (42%) prescribed MgO for constipation had documented effective bowel movements after the start of MgO, while 6 were ineffective, and 5 were unknown.

Fig. 3
figure 3

Laxative effect of MgO for constipation in 19 patients undergoing hemodialysis

Full size image

Table 4 shows the patient backgrounds of the eight patients in which MgO was effective for constipation and the six cases in which it was ineffective.

Table 4 Subgroup analysis of patients prescribed MgO for constipation
Full size table

Compared with the ineffective group, the effective group received significantly lower doses of MgO (P = 0.035), while no statistical differences were found in other patient background factors; however, one patient in the ineffective group and two in the effective group used other laxatives prior to starting MgO. None of the patients in the study had undergone gastrectomy.

Discussion

The results of the present study showed that low-dose MgO safely administered to patients undergoing HD increased serum Mg concentrations without causing excessive hypermagnesemia. A meta-analysis of eight studies including 309 patients undergoing HD showed that Mg supplementation resulted in better management of CKD-mineral bone disorder [17]. We believe that the present study is valuable because it provides a methodology for maintaining high serum Mg concentrations in patients undergoing HD. Additionally, the small sample size suggested that low-dose MgO may improve defecation in patients undergoing HD, which may be useful when considering options for treating constipation in patients undergoing HD who are at a high risk of developing chronic constipation.

Most patients in the present study continued an MgO treatment regimen of 330 mg/day, which safely increased their serum Mg concentrations (Fig. 1), and although concentrations exceeding 4.0 mg/dL were observed in a few cases, these were managed with a dose reduction. It may be possible to safely adjust the MgO dosage by monitoring serum Mg concentrations once a month. Additionally, serum Mg concentrations were more likely to be elevated in lower-weight patients (Table 3, Fig. 2), which may be the result of MgO being a fixed-dose oral drug, meaning the dose in terms of body weight is higher in patients with lower body weights. The gastrointestinal absorption of MgO involves the paracellular pathway via tight junctions and the transcellular pathway via the transient receptor potential melastatin (TRPM) 6/7 [18]. TRPM6/7 expression is regulated by Mg intake and intracellular Mg concentrations, and may cause increased Mg absorption during periods of hypomagnesemia [18]. In the present study, the baseline serum Mg concentration was not associated with changes in the serum Mg concentration (Table 3). Because the expression of claudin, a tight junction protein, is decreased in cases of renal dysfunction, resulting in a “leaky gut” [19], Mg absorption via the paracellular pathway appears to be increased in patients undergoing dialysis. Although Kt/V and serum albumin concentrations are associated with the dialysis removal of free Mg from the serum, they have no apparent effect on changes in serum Mg concentrations, as most of the Mg in the body is distributed throughout the bone and muscle. Therefore, when administering low-dose MgO in patients undergoing HD, although serum Mg concentrations are likely to increase in lower-weight patients, the routine evaluation of serum Mg concentrations may ensure a safe response.

No previous studies, however, have examined the effects of MgO supplementation on constipation in patients undergoing HD. In the subgroup analysis of patients undergoing HD who were prescribed MgO for constipation, approximately half of the patients showed an improvement in defecation (Fig. 3). Previous reports using MgO as a laxative have utilized doses of 1500 mg/day [20,21,22]; however, a much lower dose was administered to the patients undergoing HD in the present study. In contrast, in the effect of magnesium supplementation on vascular calcification in chronic kidney disease—a randomized clinical trial (MAGiCAL-CKD) study, in which Mg hydroxide was administered at a dosage of 360 mg/day to nondialyzed patients with CKD—soft stool and diarrhea were more frequent in the Mg hydroxide than the placebo group [8]. Those results indicate that even a low dose of MgO may contribute to improved defecation in patients undergoing HD. The lower dose of MgO in the effective group compared with the no-effect group is contrary to theory and the detailed cause is unknown. MgO increments associated with poor efficacy may increase the risk of hypermagnesemia, especially in dialysis patients. Since there was no rational difference in MgO dosage between the effective group and the noneffective group in this study, if constipation is not improved after low-dose MgO administration, it is advisable to avoid inadvertent increase in MgO dosage and consider adding or changing other laxatives. It has been reported that the MgO dose required to improve constipation was relatively higher in patients with concomitant gastric acid blockers [23]. However, the patient background of this previous report differs from that of the present study in that it included patients after colon surgery and the MgO alone group had a higher average MgO dose of about 1000 mg/day. In this study, it is unclear what factors prevented the concomitant use of gastric acid blockers from affecting the effect of MgO on improving constipation in patients undergoing hemodialysis. Possible factors include lower doses of MgO compared with previous reports and patients with decreased gastric acid secretion owing to complications, such as atrophic gastritis and pancreatitis. There were, however, a few cases of treatment-resistant constipation in the present study, in which patients had already shown a poor response to other laxatives (Table 4). In our previous study on the efficacy of lubiprostone in patients undergoing HD, we found that lubiprostone was effective in 75% of the patients with treatment-resistant constipation who were already using other laxatives [24]. Therefore, low-dose MgO may be one of the initial treatment options administered to patients undergoing HD with the intention of creating a laxative effect; however, it may not have a marked effect on refractory constipation.

The present study had several limitations. First, the small number of patients in the study may have influenced the statistical evaluation, especially in the investigation of factors associated with changes in serum Mg concentrations and the subgroup analysis of the effectiveness of supplemental MgO on improved defecation. Second, as the present study was conducted on outpatients undergoing HD, detailed medication histories could not be confirmed, which may also be a factor related to fluctuations in serum Mg concentrations. In practice, attention should be paid not only to medication noncompliance, but also to hypermagnesemia owing to overmedication with MgO. Third, the effects of improved defecation after the initiation of MgO supplementation were based on the patients’ chief complaints, in which there may be bias regarding the method of obtaining the information as well as patient subjectivity. Ideally, changes in bowel movements should be assessed using the Bristol Stool Form Scale (BSFS) and the Constipation Severity Score (CSS); however, these quantitative assessments are difficult to perform in a retrospective study. Since reports of improvements in constipation in patients may indicate satisfaction with defecation or laxatives, and this information is used as a reference in actual clinical practice, we believe that the effectiveness of MgO on improving defecation in patients undergoing HD in the present study cannot be denied. However, for a more quantitative and detailed investigation of the effect of low-dose MgO on improving defecation in hemodialysis patients, it would be desirable to investigate prospectively using a constipation severity scale before and after MgO initiation.

Conclusions

The results of the present study suggest that low-dose MgO administration to patients undergoing HD provides a means of increasing serum Mg concentrations without causing dangerous hypermagnesemia and that it is relatively easy to increase serum Mg concentrations in lower-weight patients. In addition, this study shows that low-dose MgO may be effective as an initial treatment for constipation in this patient group in a cautious manner, but this study did not provide sufficient data for usefulness of low-dose MgO for constipation in patients undergoing HD.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author TY on reasonable request.

Abbreviations

CKD:

Chronic kidney disease

DW:

Dry weight

HD:

Hemodialysis

HDF:

Hemodiafiltration

Kt/V :

Standardized dialysis volume

MgO:

Magnesium oxide

nPCR:

Normalized protein catabolic ratio

TRPM:

Transient receptor potential melastatin

References

  1. de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. J Am Med Assoc. 2009;302:1782–9. https://doi.org/10.1001/jama.2009.1488.

    Article  Google Scholar 

  2. Li L, Streja E, Rhee CM, Mehrotra R, Soohoo M, Brunelli SM, et al. Hypomagnesemia and mortality in incident hemodialysis patients. Am J Kidney Dis. 2015;66:1047–55. https://doi.org/10.1053/j.ajkd.2015.05.024.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Isaka Y. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int. 2014;85:174–81. https://doi.org/10.1038/ki.2013.327.

    Article  CAS  PubMed  Google Scholar 

  4. Sakaguchi Y, Hamano T, Wada A, Hoshino J, Masakane I. Magnesium and risk of hip fracture among patients undergoing hemodialysis. J Am Soc Nephrol. 2018;29:991–9. https://doi.org/10.1681/ASN.2017080849.

    Article  CAS  PubMed  Google Scholar 

  5. Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Iseki K, et al. Magnesium modifies the cardiovascular mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis: A cohort study. PLoS ONE. 2014;9: e116273. https://doi.org/10.1371/journal.pone.0116273.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Bressendorff I, Hansen D, Schou M, Silver B, Pasch A, Bouchelouche P, et al. Oral magnesium supplementation in chronic kidney disease Stages 3 and 4: efficacy, safety, and effect on serum calcification propensity-a prospective randomized double-blinded placebo-controlled clinical trial. Kidney Int Rep. 2017;2:380–9. https://doi.org/10.1016/j.ekir.2016.12.008.

    Article  PubMed  Google Scholar 

  7. Sakaguchi Y, Hamano T, Obi Y, Monden C, Oka T, Yamaguchi S, et al. A randomized trial of magnesium oxide and oral carbon adsorbent for coronary artery calcification in predialysis CKD. J Am Soc Nephrol. 2019;30:1073–85. https://doi.org/10.1681/ASN.2018111150.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Bressendorff I, Hansen D, Schou M, Kragelund C, Svensson M, Hashemi B, et al. The effect of magnesium supplementation on vascular calcification in CKD: a randomized clinical trial (MAGiCAL-CKD). J Am Soc Nephrol. 2023;34:886–94. https://doi.org/10.1681/ASN.0000000000000092.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Pasch A, Block GA, Bachtler M, Smith ER, Jahnen-Dechent W, Arampatzis S, et al. Blood calcification propensity, cardiovascular events, and survival in patients receiving hemodialysis in the EVOLVE trial. Clin J Am Soc Nephrol. 2017;12:315–22. https://doi.org/10.2215/CJN.04720416.

    Article  CAS  PubMed  Google Scholar 

  10. Zawada AM, Wolf M, Rincon Bello A, Ramos-Sanchez R, Hurtado Munoz S, Ribera Tello L, et al. Assessment of a serum calcification propensity test for the prediction of all-cause mortality among hemodialysis patients. BMC Nephrol. 2023;24:35. https://doi.org/10.1186/s12882-023-03069-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Sumida K, Yamagata K, Kovesdy CP. Constipation in CKD. Kidney Int Rep. 2020;5:121–34. https://doi.org/10.1016/j.ekir.2019.11.002.

    Article  PubMed  Google Scholar 

  12. Honda Y, Itano S, Kugimiya A, Kubo E, Yamada Y, Kimachi M, et al. Laxative use and mortality in patients on haemodialysis: a prospective cohort study. BMC Nephrol. 2021;22:363. https://doi.org/10.1186/s12882-021-02572-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Halue G, Tharapanich H, Phannajit J, Kanjanabuch T, Banjongjit A, Lorvinitnun P, et al. Constipation and clinical outcomes in peritoneal dialysis: results from Thailand PDOPPS. Nephrology (Carlton). 2023;28(Suppl 1):35–47. https://doi.org/10.1111/nep.14224.

    Article  PubMed  Google Scholar 

  14. Wakai E, Ikemura K, Sugimoto H, Iwamoto T, Okuda M. Risk factors for the development of hypermagnesemia in patients prescribed magnesium oxide: a retrospective cohort study. J Pharm Health Care Sci. 2019;5:4. https://doi.org/10.1186/s40780-019-0133-7.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Yamaguchi H, Shimada H, Yoshita K, Tsubata Y, Ikarashi K, Morioka T, et al. Severe hypermagnesemia induced by magnesium oxide ingestion: a case series. CEN Case Rep. 2019;8:31–7. https://doi.org/10.1007/s13730-018-0359-5.

    Article  PubMed  Google Scholar 

  16. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8. https://doi.org/10.1038/bmt.2012.244.

    Article  CAS  PubMed  Google Scholar 

  17. Guo G, Zhou J, Xu T, Sheng Z, Huang A, Sun L, et al. Effect of magnesium supplementation on chronic kidney disease-mineral and bone disorder in hemodialysis patients: a meta-analysis of randomized controlled trials. J Ren Nutr. 2022;32:102–11. https://doi.org/10.1053/j.jrn.2021.07.009.

    Article  CAS  PubMed  Google Scholar 

  18. Schuchardt JP, Hahn A. Intestinal absorption and factors influencing bioavailability of magnesium-an update. Curr Nutr Food Sci. 2017;13:260–78. https://doi.org/10.2174/1573401313666170427162740.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Yang J, Lim SY, Ko YS, Lee HY, Oh SW, Kim MG, et al. Intestinal barrier disruption and dysregulated mucosal immunity contribute to kidney fibrosis in chronic kidney disease. Nephrol Dial Transplant. 2019;34:419–28. https://doi.org/10.1093/ndt/gfy172.

    Article  CAS  PubMed  Google Scholar 

  20. Mori S, Tomita T, Fujimura K, Asano H, Ogawa T, Yamasaki T, et al. A randomized double-blind placebo-controlled trial on the effect of magnesium oxide in patients with chronic constipation. J Neurogastroenterol Motil. 2019;25:563–75. https://doi.org/10.5056/jnm18194.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Morishita D, Tomita T, Mori S, Kimura T, Oshima T, Fukui H, et al. Senna versus magnesium oxide for the treatment of chronic constipation: a randomized, placebo-controlled trial. Am J Gastroenterol. 2021;116:152–61. https://doi.org/10.14309/ajg.0000000000000942.

    Article  CAS  PubMed  Google Scholar 

  22. Ozaki A, Kessoku T, Tanaka K, Yamamoto A, Takahashi K, Takeda Y, et al. Effectiveness of Naldemedine compared with magnesium oxide in preventing opioid-induced constipation: a randomized controlled trial. Cancers (Basel). 2022;14:2112. https://doi.org/10.3390/cancers14092112.

    Article  CAS  PubMed  Google Scholar 

  23. Yamasaki M, Funakoshi S, Matsuda S, Imazu T, Takeda Y, Murakami T, et al. Interaction of magnesium oxide with gastric acid secretion inhibitors in clinical pharmacotherapy. Eur J Clin Pharmacol. 2014;70:921–4. https://doi.org/10.1007/s00228-014-1694-x.

    Article  CAS  PubMed  Google Scholar 

  24. Yoshida T, Furukubo T, Tanaka C, Miyake M, Sumino K, Tanaka R, et al. Clinical efficacy of lubiprostone for constipation in patients undergoing maintenance hemodialysis. J Osaka Soc Dial Ther. 2014;32:29–32.

    Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

None.

Author information

Authors and Affiliations

  1. Department of Pharmacy Services, Shirasagi Hospital, 7-11-23 Kumata, Higashisumiyoshi-ku, Osaka, 546-0002, Japan

    Takuya Yoshida & Taku Furukubo

  2. Department of Medical Technology, Shirasagi Hospital, Osaka, Japan

    Satoshi Izumi

  3. Department of Medicine, Shirasagi Hospital, Osaka, Japan

    Shigeichi Shoji & Tomoyuki Yamakawa

Authors
  1. Takuya Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Taku Furukubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Satoshi Izumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shigeichi Shoji
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomoyuki Yamakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TY performed patient enrollment, sample collection, data interpretation, statistical analyses, and manuscript writing. TF contributed to writing the manuscript. SI, SS, and TY drafted the manuscript. All of the authors have read and approved the final version of the manuscript.

Corresponding author

Correspondence to Takuya Yoshida.

Ethics declarations

Ethics approval and consent to participate

The present study was approved by the Shirasagi Hospital Ethics Committee (Approval Number JCR2023004) and performed in accordance with the Declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

The authors have no competing interests to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yoshida, T., Furukubo, T., Izumi, S. et al. Effects of low-dose magnesium oxide on elevated serum magnesium levels and improved constipation in hemodialysis patients: a single-center retrospective study. Ren Replace Ther 10, 30 (2024). https://doi.org/10.1186/s41100-024-00546-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s41100-024-00546-y

Keywords

Renal Replacement Therapy

ISSN: 2059-1381

Contact us